• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Option Care Health Inc.

    7/31/24 4:30:48 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care
    Get the next $OPCH alert in real time by email
    S-8 1 tm2419622d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on July 31, 2024

     

    Registration No. 333-________

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    OPTION CARE HEALTH, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   05-0489664
    (State or other jurisdiction of incorporation or
    organization)
      (I.R.S. Employer Identification No.)

     

    3000 Lakeside Dr., Suite 300N

    Bannockburn, IL 60015

    (Address of Principal Executive Offices, including zip code)

     

    Option Care Health, Inc. Amended and Restated 2018 Equity Incentive Plan

    (Full title of the Plans)

     

    Collin G. Smyser

    General Counsel and Corporate Secretary

    Option Care Health, Inc.

    3000 Lakeside Dr. Suite 300N

    Bannockburn, IL 60015

    (Name and address of agent for service)

     

    (312) 940-2443

    (Telephone number, including area code, of agent for service)

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer  x   Accelerated filer ¨
    Non-accelerated filer  ¨   Smaller reporting company ¨
          Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    The stockholders of Option Care Health, Inc. (the “Registrant”) approved the Option Care Health, Inc. Amended and Restated 2018 Equity Incentive Plan (as amended and restated, the “Amended and Restated Plan”) on May 15, 2024 (the “Effective Date”).

     

    This Registration Statement on Form S-8 is being filed with the Securities and Exchange Commission (the “Commission”) for the purpose of registering an additional 4,000,000 shares of common stock, par value $0.0001 per share, of the Registrant (the “Common Stock”) for issuance pursuant to the Amended and Restated Plan as of the Effective Date.

     

    PART I
    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information called for in Part I of Form S-8 is not being filed with or included in this Registration Statement (by incorporation by reference or otherwise) in accordance with the rules and regulations of the Commission.

     

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents, which have been filed with the Commission by the Registrant, pursuant to the Securities Act of 1933, as amended (the “Securities Act”) and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as applicable, are hereby incorporated by reference in, and shall be deemed to be a part of, this Registration Statement:

     

    (a)The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “2023 Annual Report”), which incorporates by reference certain portions of the Registrant’s definitive proxy statement for the Registrant’s 2024 Annual Meeting of Stockholders filed on April 3, 2024, incorporated by reference in the 2023 Annual Report;

     

    (b)The Registrant’s Quarterly Reports on Form 10-Q for the fiscal quarter ended March 31, 2024 and for the fiscal quarter ended June 30, 2024;

     

    (c)The Registrant’s Current Reports on Form 8-K filed on May 10, 2024 and May 17, 2024; and

     

    (d)The description of the Registrant’s Common Stock, included in Exhibit 4.12 to Registrant’s Form 10-K for the year ended December 31, 2020, including any amendment or report filed for the purpose of updating such description.

     

    In addition, all documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14, and 15(d) of the Exchange Act after the date of this Registration Statement and before the filing of a post-effective amendment that indicates that all shares of Common Stock offered have been sold, or that deregisters all shares of Common Stock then remaining unsold, shall be deemed to be incorporated by reference in, and to be a part of, this Registration Statement from the date of filing of those documents.

     

    Any statement contained in a document incorporated, or deemed to be incorporated, by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or incorporated herein by reference or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     2

     

     

    Notwithstanding the foregoing, nothing in this Registration Statement shall be deemed to incorporate any information from Item 2.02 or Item 7.01 of any Form 8-K, or that is otherwise furnished under applicable Commission rules rather than filed, or any exhibits to the extent furnished in connection with such items.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    Section 102 of the General Corporation Law of the State of Delaware (the “DGCL”) allows a corporation to eliminate the personal liability of directors and certain officers to a corporation or its stockholders for monetary damages for a breach of a fiduciary duty as a director or officer, except where the director or officer breached their duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law or obtained an improper personal benefit or where the director authorized the payment of a dividend or approved a stock repurchase or redemption in violation of Delaware corporate law.

     

    Section 145 of the DGCL empowers a Delaware corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation) by reason of the fact that such person is or was a director, officer, employee or agent of such corporation, or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise. The indemnity may include expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided that such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person’s conduct was unlawful. A Delaware corporation may indemnify directors, officers, employees and other agents of such corporation in an action by or in the right of a corporation under the same conditions against expenses (including attorneys’ fees) actually and reasonably incurred by the person in connection with the defense and settlement of such action or suit, except that no indemnification is permitted without judicial approval if the person to be indemnified has been adjudged to be liable to the corporation. Where a present or former director or officer of the corporation is successful on the merits or otherwise in the defense of any action, suit or proceeding referred to above or in defense of any claim, issue or matter therein, the corporation must indemnify such person against the expenses (including attorneys’ fees) which he or she actually and reasonably incurred in connection therewith.

     

    Section 174 of the DGCL provides, among other things, that a director who willfully or negligently approves of an unlawful payment of dividends or an unlawful stock purchase or redemption, may be held liable for such actions. A director who was either absent when the unlawful actions were approved or dissented at the time, may avoid liability by causing their dissent to such actions to be entered into the books containing the minutes of the meetings of the board of directors at the time such action occurred or immediately after such absent director receives notice of the unlawful acts.

     

    The Registrant’s bylaws provide that any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that such person is or was a director or officer of the Registrant, or is or was serving while a director or officer of the Registrant at the request of the Registrant as a director, officer, employee, agent, fiduciary or other representative of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise, shall be indemnified by the Registrant against expenses (including attorneys’ fees), judgments, fines, excise taxes and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding to the full extent permissible under Delaware law.

     

     3

     

     

    In addition, the Registrant’s bylaws provide that the Registrant shall have power to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the Registrant or is or was serving at the request of the Registrant as a director, officer, employee, agent, fiduciary or other representative of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise, against any liability asserted against them and incurred by them in any such capacity, or arising out of their status as such, whether or not the Registrant would have the power to indemnify them against such liability under the provisions of the bylaws.

     

    The Registrant currently maintains directors and officers liability insurance.

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

    Exhibit No.   Description
    3.1   Third Amended and Restated Certificate of Incorporation of BioScrip, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on August 7, 2019).
    3.2   Certificate of Amendment to Certificate of Incorporation, amending the Third Amended and Restated Certificate of Incorporation of BioScrip, Inc. (incorporated by reference to Exhibit 3.3 to the Registrant’s Current Report on Form 8-K filed on August 7, 2019).
    3.3   Certificate of Amendment of the Certificate of Incorporation, filed January 30, 2020 (incorporated by reference to Exhibit 3.4 to the Registrant’s Annual Report on Form 10-K filed on March 11, 2021).
    3.4   Fourth Amended and Restated By-Laws of Option Care Health, Inc., effective as of December 6, 2023 (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on December 11, 2023).
    5.1   Opinion of Faegre Drinker Biddle & Reath LLP.
    10.1   Option Care Health, Inc. Amended and Restated 2018 Equity Incentive Plan (incorporated by reference to Appendix B to the Registrant’s Definitive Proxy Statement for the 2024 Annual Meeting of Stockholders filed on April 3, 2024).
    23.1   Consent of KPMG LLP, Independent Registered Public Accounting Firm.
    23.2   Consent of Faegre Drinker Biddle & Reath LLP (included in Exhibit 5.1).
    24.1   Powers of Attorney (included on the Signature Page of this Registration Statement).
    107   Filing Fee Table.

     

    Item 9. Undertakings.

     

    (a)            The undersigned Registrant hereby undertakes:

     

    (1)            To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i)            To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

     

    (ii)           To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and

     

     4

     

     

    (iii)          To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Securities and Exchange Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the Registration Statement.

     

    (2)            That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3)            To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b)            The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c)            Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.

     

     5

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Bannockburn, State of Illinois, on July 31, 2024.

     

      OPTION CARE HEALTH, INC.
         
      By:  /s/ John C. Rademacher
        John C. Rademacher
        Chief Executive Officer and President

     

    SIGNATURES AND POWER OF ATTORNEY

     

    We, the undersigned officers and directors of Option Care Health, Inc., hereby severally constitute and appoint John C. Rademacher, Michael Shapiro and Collin Smyser, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement (or any other registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Signature   Title   Date
             
    /s/ John C. Rademacher   Chief Executive Officer, President and Director   July 31, 2024
    John C. Rademacher   (Principal Executive Officer)    
             
    /s/ Michael Shapiro   Chief Financial Officer and Executive Vice President   July 31, 2024
    Michael Shapiro   (Principal Financial Officer and Principal Accounting Officer)    
             
    /s/ Harry M. Jansen Kraemer, Jr.   Non-Executive Chairman of the Board   July 31, 2024
    Harry M. Jansen Kraemer, Jr.        
             
    /s/ John J. Arlotta   Director   July 31, 2024
    John J. Arlotta        
             
    /s/ Elizabeth D. Bierbower   Director   July 31, 2024
    Elizabeth D. Bierbower        
             
    /s/ Elizabeth Q. Betten   Director   July 31, 2024
    Elizabeth Q. Betten        
             
    /s/ Barbara W. Bodem   Director   July 31, 2024
    Barbara W. Bodem        
             
    /s/ Eric K. Brandt   Director   July 31, 2024
    Eric K. Brandt        
             
    /s/ Natasha Deckmann   Director   July 31, 2024
    Natasha Deckmann        
             
    /s/ David W. Golding   Director   July 31, 2024
    David W. Golding        
             
    /s/ R. Carter Pate   Director   July 31, 2024
    R. Carter Pate        
             
    /s/ Timothy P. Sullivan   Director   July 31, 2024
    Timothy P. Sullivan        
             
    /s/ Norman L. Wright   Director   July 31, 2024
    Norman L. Wright        

     

     6

     

    Get the next $OPCH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OPCH

    DatePrice TargetRatingAnalyst
    12/11/2025$40.00Overweight
    Stephens
    10/2/2025$30.00Hold
    TD Cowen
    4/30/2025$40.00Neutral → Buy
    UBS
    1/23/2025$26.00 → $35.00Hold → Buy
    Jefferies
    1/13/2025$26.00 → $33.00Neutral → Buy
    BofA Securities
    12/5/2024$26.00Neutral
    UBS
    11/4/2024$27.00Buy → Neutral
    Goldman
    10/31/2024$38.00 → $26.00Buy → Hold
    Jefferies
    More analyst ratings

    $OPCH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Option Care Health to Participate in the TD Cowen Healthcare Conference

    BANNOCKBURN, Ill., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. ("Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, will participate in the 46th Annual TD Cowen Healthcare Conference, being held in Boston, MA, on Tuesday, March 3, 2026, including a fireside chat at 1:10pm ET. The webcast will be available online at https://investors.optioncarehealth.com. About Option Care Health Option Care Health is the nation's largest independent provider of home and alternate site infusion services. With over 8,000 team members including more than 5,000 clinicians, we work compassionately to elevate standards of c

    1/29/26 4:05:00 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    Option Care Health to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call

    BANNOCKBURN, Ill., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Option Care Health Inc. ("Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, today announced that the company will release results for its fourth quarter and full year 2025 on Tuesday, February 24, 2026 before the market opens. In conjunction, the management team will host a conference call to review the results at 8:30 a.m. E.T. on the same day. Conference Call DetailsParticipants can pre-register for the conference call at the following link: https://register-conf.media-server.com/register/BIf3f7a42783bf4a85aae626ffa262fb95. The call can also be accessed via a li

    1/21/26 4:05:00 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    Option Care Health Announces Preliminary Fourth Quarter & Full Year 2025 Financial Results and Preliminary Financial Guidance for Full Year 2026

    BANNOCKBURN, Ill., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the "Company" or "Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, announced today preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025, and preliminary financial guidance for the full year 2026. (Year-over-year comparisons unless otherwise noted; Growth comparisons versus midpoint of range) Fourth Quarter 2025 Preliminary Expected Results Net revenue of $1.46 billion to $1.47 billionGAAP net income of $59.1 million to $62.4 millionGAAP diluted EPS of $0.37 to $0.39Adjusted diluted EPS of

    1/12/26 4:35:00 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    $OPCH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kraemer Harry M Jansen Jr bought $987,392 worth of shares (38,000 units at $25.98), increasing direct ownership by 10% to 413,390 units (SEC Form 4)

    4 - Option Care Health, Inc. (0001014739) (Issuer)

    11/4/25 4:30:07 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    Director Wright Norman L. bought $99,976 worth of shares (3,411 units at $29.31), increasing direct ownership by 28% to 15,501 units (SEC Form 4)

    4 - Option Care Health, Inc. (0001014739) (Issuer)

    9/10/25 4:18:22 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    Director Pate R Carter bought $20,391 worth of shares (750 units at $27.19), increasing direct ownership by 2% to 41,910 units (SEC Form 4)

    4 - Option Care Health, Inc. (0001014739) (Issuer)

    8/21/25 6:26:07 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    $OPCH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stephens initiated coverage on Option Care Health with a new price target

    Stephens initiated coverage of Option Care Health with a rating of Overweight and set a new price target of $40.00

    12/11/25 9:11:57 AM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    TD Cowen initiated coverage on Option Care Health with a new price target

    TD Cowen initiated coverage of Option Care Health with a rating of Hold and set a new price target of $30.00

    10/2/25 8:41:19 AM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    Option Care Health upgraded by UBS with a new price target

    UBS upgraded Option Care Health from Neutral to Buy and set a new price target of $40.00

    4/30/25 7:24:45 AM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    $OPCH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kraemer Harry M Jansen Jr bought $987,392 worth of shares (38,000 units at $25.98), increasing direct ownership by 10% to 413,390 units (SEC Form 4)

    4 - Option Care Health, Inc. (0001014739) (Issuer)

    11/4/25 4:30:07 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    Chief Financial Officer Sethna Meenal was granted 55,067 shares (SEC Form 4)

    4 - Option Care Health, Inc. (0001014739) (Issuer)

    10/3/25 4:15:09 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    SEC Form 3 filed by new insider Sethna Meenal

    3 - Option Care Health, Inc. (0001014739) (Issuer)

    10/3/25 4:13:19 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    $OPCH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Option Care Health Inc.

    SC 13G - Option Care Health, Inc. (0001014739) (Subject)

    11/8/24 10:46:38 AM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G/A filed by Option Care Health Inc. (Amendment)

    SC 13G/A - Option Care Health, Inc. (0001014739) (Subject)

    2/13/24 5:12:03 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G/A filed by Option Care Health Inc. (Amendment)

    SC 13G/A - Option Care Health, Inc. (0001014739) (Subject)

    9/11/23 1:33:44 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    $OPCH
    SEC Filings

    View All

    Option Care Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Option Care Health, Inc. (0001014739) (Filer)

    1/12/26 4:31:31 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    SEC Form SCHEDULE 13G filed by Option Care Health Inc.

    SCHEDULE 13G - Option Care Health, Inc. (0001014739) (Subject)

    11/5/25 11:40:14 AM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    SEC Form 10-Q filed by Option Care Health Inc.

    10-Q - Option Care Health, Inc. (0001014739) (Filer)

    10/30/25 4:02:19 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    $OPCH
    Financials

    Live finance-specific insights

    View All

    Option Care Health to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call

    BANNOCKBURN, Ill., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Option Care Health Inc. ("Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, today announced that the company will release results for its fourth quarter and full year 2025 on Tuesday, February 24, 2026 before the market opens. In conjunction, the management team will host a conference call to review the results at 8:30 a.m. E.T. on the same day. Conference Call DetailsParticipants can pre-register for the conference call at the following link: https://register-conf.media-server.com/register/BIf3f7a42783bf4a85aae626ffa262fb95. The call can also be accessed via a li

    1/21/26 4:05:00 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    Option Care Health Announces Financial Results For the Third Quarter Ended September 30, 2025

    BANNOCKBURN, Ill., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the "Company" or "Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, announced today financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights (Year-over-year comparisons unless otherwise noted) Net revenue of $1,435.0 million, up 12.2%Gross profit of $272.9 million, up 6.3%Net income of $51.8 million, down 3.8%GAAP diluted earnings per share of $0.32, up 3.2%Adjusted EBITDA of $119.5 million, up 3.4%Adjusted diluted earnings per share of $0.45, up 9.8%YTD cash provided by operating activit

    10/30/25 7:00:00 AM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    Option Care Health to Announce Third Quarter 2025 Financial Results and Host Conference Call

    BANNOCKBURN, Ill., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Option Care Health Inc. ("Option Care Health") (NASDAQ: OPCH), the nation's largest independent provider of home and alternate site infusion services, today announced that the company will release results for its third quarter ended September 30, 2025 on Thursday, October 30, 2025 before the market opens. In conjunction, the management team will host a conference call to review the results at 8:30 a.m. E.T. on the same day. Conference Call DetailsParticipants can pre-register for the conference call at the following link: https://register-conf.media-server.com/register/BI9e5bd109ef23408dbd76380aed8d4b05. The call can also be accessed v

    9/25/25 4:05:00 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    $OPCH
    Leadership Updates

    Live Leadership Updates

    View All

    Option Care Health Announces Chief Financial Officer Transition

    BANNOCKBURN, Ill., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the "Company" or "Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, announced the appointment of Meenal Sethna as Executive Vice President and Chief Financial Officer, effective October 1, 2025. Sethna will succeed Mike Shapiro, who has decided to step down as CFO effective September 30, 2025, following a decade of service to the Company. At the time of the transition, Shapiro will remain with the Company as a Strategic Advisor through at least the first quarter of 2026 to continue to help advance the Company's strategy and ensure a smooth

    8/20/25 8:45:00 AM ET
    $LFUS
    $OPCH
    Electrical Products
    Energy
    Medical/Nursing Services
    Health Care

    Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

    Marks major milestone with completion of enrollment in pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T; topline results expected in first quarter of 2026 Closed financing priced at a premium bringing existing cash position to approximately $35 million; expected to provide runway through Phase 3 topline results and into at least second quarter of 2026 Entered into strategic relationship with Option Care Health to support commercial launch of eDSP in the U.S. Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an

    8/11/25 4:05:00 PM ET
    $OPCH
    $QNCX
    Medical/Nursing Services
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers

    NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and

    2/27/24 9:00:00 AM ET
    $BMRN
    $ENOV
    $OPCH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties
    Medical/Nursing Services